Onconetix, Inc. (ONCO)
NASDAQ: ONCO · Real-Time Price · USD
0.0696
+0.0006 (0.87%)
At close: Apr 25, 2025, 4:00 PM
0.0693
-0.0003 (-0.43%)
After-hours: Apr 25, 2025, 5:25 PM EDT
Company Description
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology.
It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023.
Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Onconetix, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Feb 18, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Karina Fedasz |
Contact Details
Address: 201 East Fifth Street, Suite 1900 Cincinnati, Ohio 45202 United States | |
| Phone | 513 620 4101 |
| Website | onconetix.gcs-web.com |
Stock Details
| Ticker Symbol | ONCO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $9.00 |
| CIK Code | 0001782107 |
| CUSIP Number | 682160106 |
| ISIN Number | US09610B1089 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Karina M. Fedasz | Interim Chief Executive Officer and Interim Chief Financial Officer |
| Andrew D. Skibo Ph.D. | Global Head of Biologics Operations |
| Dr. Brian Price Ph.D. | Head of Technology Strategy |
| Theodore Scott Yoho | Head of Business Development |
| Dr. Ali I. Fattom Ph.D. | Head of Science and Discovery |
| Dr. Jay Newmark M.B.A., M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 18, 2025 | 8-K | Current Report |
| Apr 8, 2025 | 8-K | Current Report |
| Apr 3, 2025 | 8-K | Current Report |
| Apr 1, 2025 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 24, 2025 | 8-K | Current Report |
| Mar 19, 2025 | 8-K | Current Report |
| Feb 28, 2025 | 8-K | Current Report |
| Feb 18, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13D/A | Filing |